Upstream Bio, Inc. (NASDAQ:UPB) Receives $39.00 Average PT from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has received an average recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $39.00.

Several research firms have weighed in on UPB. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research report on Friday, March 27th. Finally, Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in Upstream Bio in the fourth quarter worth $29,000. Torren Management LLC purchased a new position in Upstream Bio in the fourth quarter worth $30,000. Empowered Funds LLC purchased a new position in Upstream Bio in the fourth quarter worth $45,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Upstream Bio in the fourth quarter worth $71,000. Finally, Russell Investments Group Ltd. boosted its position in Upstream Bio by 1,963.9% in the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares during the last quarter.

Upstream Bio Trading Up 2.4%

Shares of Upstream Bio stock opened at $9.51 on Wednesday. The stock has a fifty day simple moving average of $9.00 and a 200 day simple moving average of $20.15. Upstream Bio has a 12-month low of $7.25 and a 12-month high of $33.68. The company has a market capitalization of $517.53 million, a P/E ratio of -3.56 and a beta of 1.80.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%.The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.52 million. On average, analysts predict that Upstream Bio will post -3.02 EPS for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.